Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
:ILMN
Holding ILMN?
Track your performance easily
ILMN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$100.09 - $156.66
Previous CloseN/A
Volume388.94K
Average Volume (3M)1.97M
Market Cap
$21.79B
Enterprise Value$22.55B
Total Cash (Recent Filing)$1.56B
Total Debt (Recent Filing)$1.06B
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Feb 06, 2025EPS Estimate
0.92Last Dividend Ex-Date
Jun 25, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-10.00
Shares Outstanding158,600,000
10 Day Avg. Volume1,719,465
30 Day Avg. Volume1,969,999
Standard Deviation0.12
R-Squared0.25
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.96
Price to Cash Flow (P/CF)17.20
P/FCF Ratio19.20
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue5.14
Enterprise Value/Gross Profit8.22
Enterprise Value/Ebitda-20.83
Forecast
1Y Price Target
$163.40Price Target Upside19.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Illumina News
Bulls Say, Bears Say
Bulls Say
EarningsILMN preannounced top line revenue of $1.10B, beating estimates.
Market LeadershipILMN is a clear market leader in the next-generation sequencing (NGS) space, with leading market share via its differentiated NGS platform that has enabled high throughput sequencing at increasingly lower cost while simplifying the customer workflow.
Product DevelopmentThe rollout of the NovaSeq X instrument is progressing nicely, especially from a clinical penetration perspective.
Bears Say
Financial PerformanceThe guidance for constant currency sales growth in '25 is on the lower end, with a reported sales growth of only 0.2%, reflecting challenges in achieving higher sales figures.
Market CompetitionUltima Genomics announced that its UG 100 HT sequencer was selected as the primary sequencing platform reading out UK Biobank's new Proteome study, bringing more competition into the research end-market and is a negative for ILMN's research business.
Revenue GuidanceInitial guidance for FY25 revenue is below consensus expectations, which might raise concerns about growth.
---
Ownership Overview
0.23% Insiders
23.97% Mutual Funds
0.77% Other Institutional Investors
52.50% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $100.08 and its highest was $156.66 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $21.79B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Feb 06, 2025 which is in 16 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Nov 04, 2024. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.879 by $0.261.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina pays a Notavailable dividend of $3.104 which represents an annual dividend yield of N/A. See more information on Illumina dividends here
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 0.92.
How many shares outstanding does Illumina have?
Illumina has 158,600,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.14 in its last earnings report, beating expectations of $0.879. Following the earnings report the stock price went up 0.958%.
Which hedge fund is a major shareholder of Illumina?
Among the largest hedge funds holding Illumina’s share is Guardcap Asset Management Ltd. It holds Illumina’s shares valued at 355M.
---
Illumina Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$163.40 (19.56% Upside)
$163.40 (19.56% Upside)
Blogger Sentiment
Bullish
ILMN Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.29%
12-Months-Change
Fundamentals
Return on Equity
-39.51%
Trailing 12-Months
Asset Growth
-40.58%
Trailing 12-Months
Company Description
Illumina
Incorporated in 1998, Illumina, Inc. is a California-based company which develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting.
---
ILMN Company Deck
---
ILMN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
Illumina's earnings call highlighted strong financial performance, significant milestones in the NovaSeq X platform, and robust cash flow management. However, regional revenue declines, notably in the Americas and Greater China, and a significant drop in sequencing instruments revenue were concerning. The company adjusted its revenue guidance downward due to ongoing macroeconomic constraints and competitive pressures in the mid-throughput segment.Read More>---
ILMN Revenue Breakdown
91.30% Sequencing
8.70% Microarray
---
ILMN Stock 12 Month Forecast
Average Price Target
$163.40
▲(19.56% Upside)
Technical Analysis
Best Analysts Covering ILMN
1 Year
1 Year Success Rate
24/30 ratings generated profit
1 Year Average Return
+18.86%
reiterated a buy rating 8 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +18.86% per trade.
---